ClinicalTrials.gov
ClinicalTrials.gov Menu

Tipifarnib in Treating Patients With Myeloproliferative Disorders

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00005846
Recruitment Status : Unknown
Verified July 2005 by National Cancer Institute (NCI).
Recruitment status was:  Active, not recruiting
First Posted : January 27, 2003
Last Update Posted : June 7, 2011
Sponsor:
Collaborator:
National Cancer Institute (NCI)
Information provided by:
National Cancer Institute (NCI)

No Study Results Posted on ClinicalTrials.gov for this Study
  Recruitment Status : Unknown
  Primary Completion Date : No date given
  Study Completion Date : No date given
Publications of Results:
Gotlib J, Loh M, Vattikuti S, et al.: Phase I/II study of tipifarnib (ZARNESTRA, farnesyltransferase inhibitor [FTI] R115777) in patients with myeloproliferative disorders(MPDs): preliminary results. [Abstract] Blood 100 (Suppl 1): 798a, 2002.